EMCDDA
| European Monitoring Centre for Drugs and Drug Addiction | |
|---|---|
| [[File:|250px|alt=]] | |
| Formation | 1993 |
| Type | European Union agency |
| Headquarters | Lisbon, Portugal |
| Membership | N/A |
| Language | N/A |
| Leader title | N/A |
| Leader name | N/A |
| Website | emcdda.europa.eu |
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is an agency of the European Union established in 1993. It is headquartered in Lisbon, Portugal. The EMCDDA provides the EU and its member states with a factual overview of European drug problems and a solid evidence base to support the drugs debate.
History[edit | edit source]
The EMCDDA was established by Council Regulation (EEC) No 302/93 of 8 February 1993. It was created to provide the European Community and its member states with "objective, reliable and comparable information" on drugs and drug addiction.
Objectives[edit | edit source]
The main objectives of the EMCDDA are to:
- Collect and analyze information on drug use and drug addiction in Europe.
- Monitor the drug situation and the responses to it.
- Disseminate data and information on drugs and drug addiction.
- Develop tools and instruments to improve the quality of data collection and analysis.
Activities[edit | edit source]
The EMCDDA carries out a range of activities, including:
- Publishing an annual report on the state of the drug problem in Europe.
- Operating the European Drug Report and the European Drug Emergencies Network (Euro-DEN).
- Conducting studies and surveys on various aspects of drug use and addiction.
- Collaborating with national and international organizations to improve data collection and analysis.
Structure[edit | edit source]
The EMCDDA is governed by a Management Board, which includes representatives from each EU member state, the European Commission, and the European Parliament. The agency is led by a Director, who is responsible for its day-to-day operations.
See also[edit | edit source]
External links[edit | edit source]
Template:European Union agencies Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
